Pareptide monohydrochloride

Cat. No.: HY-U00271: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Pareptide monohydrochloride is a melanotropin-inhibiting factor (MIF) metabolically stable analogue.

For research use only. We do not sell to patients.

Pareptide monohydrochloride Chemical Structure

CAS No. : 63236-23-7

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description	Pareptide monohydrochloride is a melanotropin-inhibiting factor (MIF) metabolically stable analogue.
In Vivo	Chronic coadministration of Pareptide (0.25 mg/kg, SC, BID, 3.5 days) to mice pretreated with Haloperidol (8.0 mg/kg, IP, BID, 3 days) significantly increases the cataleptic effects of a smaller challenge dose of Haloperidol (2.0 mg/kg, IP) given 15 hours after the last pretreatment injections (p<0.01)^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight	334.84
Formula	C₁₄H₂₇ClN₄O₃
CAS No.	63236-23-7
SMILES	O=C([C@@H]1CCCN1)N(C)[C@H](CC(C)C)C(NCC(N)=O)=O.Cl
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (270 KB) Handling Instructions (2659 KB)
References	[1]. Mycroft FJ, et al. Pro-Leu-Gly-NH2 and Pareptide inhibit development of tolerance to Haloperidol catalepsy in the mouse. Peptides. 1984 Sep-Oct;5(5):883-7. [Content Brief]

Animal Administration
^[1]

Mice^[1]
Male albino mice of a Swiss-Webster derived strain and eighing from 26-34 g are used. Single doses of MIF-I (0.03-2.0 mg/kg, SC) and chronic pretreatments with MIF-I (0,03-2.0 mg/kg, SC, BID, 3.5 days) or Pareptide (0.25 mg/kg, SC, BID, 3.5 days) do not affect the acute cataleptic response to Haloperidol in the mouse. Pareptide is given SC in a 5 mL/kg injection volume. Chronic pretreatment with Haloperidol (8.0 mg/kg, IP, BID, 3 days) decreases the duration of catalepsy in mice given smaller challenge doses of Haloperidol (2.0 or 3.0 mg/kg, IP) 15 hours after the last pretreatment injections. Administration of either MIF-I or Pareptide to mice also chronically pretreated with Haloperidol antagonizes the development of tolerance^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Mycroft FJ, et al. Pro-Leu-Gly-NH2 and Pareptide inhibit development of tolerance to Haloperidol catalepsy in the mouse. Peptides. 1984 Sep-Oct;5(5):883-7. [Content Brief]